Loading company
Kazia Therapeutics Ltd.
KZIA · Nasdaq · ·
Next earnings: November 6, 2026
$9.78+0.9%Sep 29 close
- 1M
- -28.0%
- 6M
- +33.8%
- 1Y
- +35.6%
- 5Y
- -98.3%
Trailing twelve months where a flow is involved, latest reported balance where it is not.
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.
$29.26K2025-98.2%
Everything the company sold, before any costs. One bar per fiscal year, as filed. Stops at the last completed year.
-$15.89MQ4 2025-10.1%
What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.
-49,290.5%2025-4,148.4%
How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. One point per fiscal year, as filed. Stops at the last completed year.
-$6.04M2018+24.3%
Cash left over after running and maintaining the business. One bar per fiscal year, as filed. Stops at the last completed year.
$1.13Q4 2025+4,375.7%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.
1.12BQ4 2025+103.6%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.
8.4xQ2 2025-2.5%
Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.
$0.00Q4 2025
Cash handed to shareholders. A flat line at zero means the company pays none. Each bar sums the four quarters ending there — a full year, brought up to today.
Everything above comes from Kazia Therapeutics Ltd.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted. This company files in AUD. Figures are converted to US dollars at $1.00 = 1.4352 AUD, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s.
Share-count jumps we cannot explain: 0.10x around Jun 30, 2018, 1.61x around Jun 30, 2021, 1.43x around Jun 30, 2024, and 2.08x around Jun 30, 2025. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.
Not reported by this filer: Cost of Revenue, Gross Profit, Total Operating Expenses, Operating Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Inventory, Long-term Debt (noncurrent), Long-term Debt (current), Borrowings (total), Operating Lease (noncurrent), Operating Lease (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
KZIA · Nasdaq · ·
Next earnings: November 6, 2026
$9.78+0.9%Sep 29 close